0
selected
-
1.
Effect of probiotics supplementation combined with WeChat platform health management on nutritional status, inflammatory factors, and quality of life in patients with mild-to-moderate ulcerative colitis: a randomized trial.
Ou, Q, Wang, L, Wang, K, Shao, P
Annals of palliative medicine. 2021;(6):6606-6616
Abstract
BACKGROUND Ulcerative colitis (UC) is a refractory disease which is difficult to cure, is increasing in incidence, and is expensive to manage. The impact of long-term remission and recurrence in UC patients can cause a loss of confidence in patients regarding the efficacy of treatment and a lack of compliance, which creates a vicious circle. There is a lack of research on the nutritional status and quality of life (QOL) of UC patients in China. Therefore, the objective of this study was to evaluate the effects of probiotics supplementation combined with WeChat platform health management on the nutritional status, inflammatory factor levels, and QOL of patients with mild to moderate UC. METHODS We enrolled 150 patients diagnosed with mild to moderate UC in the outpatient and inpatient department of the Affiliated Hospital of Jiangnan University between January 2018 to December 2020. Patients were randomly divided into an intervention group (probiotics supplement combined with WeChat platform) and a control group (routine follow-up). Changes to the nutritional status, inflammatory factor levels, and QOL of patients at discharge and 12 weeks after discharge were compared. RESULTS After 12 weeks of intervention, the nutritional status, inflammatory factor levels, and QOL scores of the two groups were improved compared with those before 12 weeks. Nutritional status related indicators (PA, ALB, and TP) of the intervention group were significantly higher than those of the control group (P<0.05); the inflammatory factors (IL-6, IL-8, and TNF-α) of the intervention group were significantly lower than those of the control group (P<0.05); the SF-36 scores (PF, RP, and SF) in the intervention group were significantly higher than those in the control group (P<0.05); and the IBDQ scores (BS, SS, and EF) in the intervention group were significantly higher than those in the control group (P<0.05). CONCLUSIONS Probiotics supplements combined with WeChat platform health management have a better curative effect on UC than conventional treatment by significantly improving the nutritional status of patients, reducing the level of inflammatory factors, and improving the QOL of patients. This intervention adds value to the management of UC patients. TRIAL REGISTRATION Chinese Clinical Trial Registry ChiCTR2100046446.
-
2.
Within-trial cost-effectiveness of lifestyle intervention using a 3-tier shared care approach for pregnancy outcomes in Chinese women with gestational diabetes.
Li, W, Zhang, C, Leng, J, Shao, P, Tian, H, Zhang, F, Dong, L, Yu, Z, Chan, JCN, Hu, G, et al
PloS one. 2020;(8):e0237738
Abstract
This study assessed within-trial cost-effectiveness of a shared care program (SC, n = 339) for pregnancy outcomes compared to usual care (UC, n = 361), as implemented in a randomized trial of Chinese women with gestational diabetes (GDM). SC consisted of an individualized dietary advice and physical activity counseling program. The UC was a one-time group education program. The effectiveness was measured by number needed to treat (NNT) to prevent one macrosomia/large for gestational age (LGA) infant. The cost-effectiveness was measured by incremental cost-effectiveness ratio in terms of cost (2012 Chinese Yuan/US dollar) per case of macrosomia and LGA prevented. The study took both a health care system and a societal perspective. This study found that the NNT was 16/14 for macrosomia/LGA. The incremental cost for treating a pregnant woman was ¥1,877 ($298) from a health care system perspective and ¥2,056 ($327) from a societal perspective. The cost of preventing a case of macrosomia/LGA from the two corresponding perspectives were ¥30,032/¥26,278 ($4,775/$4,178) and ¥32,896/¥28,784 ($5,230/$4,577), respectively. Considering the potential severe adverse health and economic consequences of a macrosomia/LGA infant, our findings suggest that implementing this lifestyle intervention for women with GDM is an efficient use of health care resources.
-
3.
Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials.
Wu, RR, Zhang, FY, Gao, KM, Ou, JJ, Shao, P, Jin, H, Guo, WB, Chan, PK, Zhao, JP
Molecular psychiatry. 2016;(11):1537-1544
-
-
Free full text
-
Abstract
Dyslipidemia is one of the most common adverse effects in schizophrenia patients treated with antipsychotics. However, there are no established effective treatments. In this study, data were pooled from two randomized, placebo-controlled trials, which were originally designed to examine the efficacy of metformin in treating antipsychotic-induced weight gain and other metabolic abnormalities. In total, 201 schizophrenia patients with dyslipidemia after being treated with an antipsychotic were assigned to take 1000 mg day-1 metformin (n=103) or placebo (n=98) for 24 weeks, with evaluation at baseline, week 12 and week 24. The primary outcome was the low-density lipoprotein cholesterol (LDL-C) levels. After metformin treatment, the mean difference in the LDL-C value between metformin treatment and placebo was from 0.16 mmol l-1 at baseline to -0.86 mmol l-1 at the end of week 24, decreased by 1.02 mmol l-1 (P<0.0001); and 25.3% of patients in the metformin group had LDL-C ≥3.37 mmol l-1, which is significantly <64.8% in the placebo group (P<0.001) at week 24. Compared with the placebo, metformin treatment also have a significant effect on reducing weight, body mass index, insulin, insulin resistance index, total cholesterol and triglyceride, and increasing high-density lipoprotein cholesterol. The treatment effects on weight and insulin resistance appeared at week 12 and further improved at week 24, but the effects on improving dyslipidemia only significantly occurred at the end of week 24. We found that metformin treatment was effective in improving antipsychotic-induced dyslipidemia and insulin resistance, and the effects improving antipsychotic-induced insulin resistance appeared earlier than the reducing dyslipidemia.
-
4.
[Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia].
Shao, P, Ou, J, Wu, R, Fang, M, Chen, H, Xu, Y, Zhao, J
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences. 2013;(4):365-9
Abstract
OBJECTIVE To investigate the effect of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia. METHODS A total of 260 schizophrenics were assigned randomly to receive ziprasidone or olanzapine for 6 weeks. The weight was measured at baseline, week 2, 4 and 6. Fasting blood glucose (FBS), fasting insulin, high-density lipoprotein (HDL), total-cholesterol (TC) and triglycerides (TG) were measured at baseline and the end of 6-week treatment. Low-density lipoprotein (LDL) was measured in some patients at baseline and the end of 6-week treatment. Body mass index (BMI) and insulin resistance index (IRI) were counted. RESULTS A total of 245 patients completed the trial, including 121 ziprasidone patients and 124 olanzapine patients. The average dose was 137.5 mg/d for ziprasidone and 19.5 mg/d for olanzapine. Patients treated with olanzapine had higher weight gain than those treated with ziprasidone [(4.55±3.37) kg vs (-0.83±2.05) kg, P<0.001]. After the treatment, FBS, fasting insulin, HDL, TC, TG, LDL and IRI levels were significantly increased in the olanzapine group (all P values<0.001 ). However, in the ziprasidone group, FBS decreased significantly and HDL and TG levels increased significantly after the 6-week treatment (all P values<0.05). The mean changes of FBS, fasting insulin, TC, TG, LDL and IRI were significantly different in the two groups (all P values<0.001). CONCLUSION Ziprasidone has less glucose and lipid metabolic effect for first-episode schizophrenia patients in short-term treatment. However, olanzapine induces weight gain and dysfunction of glucose and lipid metabolism significantly, which is associated with increased risk of complications. When the doctors choose antipsychotics in the clinic, they should consider the side effects of the medication.